［1］ MARSCHALEK R.Mixed lineage leukemia:roles in human malignancies and potential therapy［J］. FEBS J,2010,277(8):1822-1831.
［2］ GRIMWADE D,IVEY A,HUNTLY BJ.Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance［J］. Blood,2016,127(1):29-41.
［3］ CHRISTOTT T,BENNETT J,COXON C,et al. Discovery of a selective inhibitor for the YEATS domains of ENL/AF9［J］. SLAS Discov,2019,24(2):133-141.
［4］ MOUSTAKIM M,CHRISTOTT T,MONTEIRO OP,et al. Discovery of an MLLT1/3 YEATS domain chemical probe［J］. Angew Chem Int Ed Engl,2018,57(50):16302-16307.
［5］ ZHANG T,LUO Y,WANG T,et al. MicroRNA-297b-5p/3p target Mllt3/Af9 to suppress lymphoma cell proliferation,migration and invasion in vitro and tumor growth in nude mice［J］. Leuk Lymphoma,2012,53(10):2033-2040.
［6］ LI Y,WEN H,XI Y,et al.AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation［J］. Cell,2014,159(3):558-571.
［7］ LIU Y,CHENG H,GAO S,et al. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells［J］. Leukemia,2014,28(5):1071-1080.
［8］ LI Y,SABARI BR,PANCHENKO T,et al. Molecular coupling of histone crotonylation and active transcription by AF9 YEATS Domain［J］. Mol Cell,2016,62(2):181-193.
［9］ ZHOU J,NG Y,CHNG WJ. ENL:structure,function,and roles in hematopoiesis and acute myeloid leukemia［J］. Cell Mol Life Sci,2018,75(21):3931-3941.
［10］ ZHAO D,LI Y,XIONG X,et al. YEATS domain-a histone acylation reader in health and disease［J］. J Mol Biol,2017,429(13):1994-2002.
［11］ HEUSER M. Therapy-related myeloid neoplasms:does knowing the origin help to guide treatment［J］. Hematology Am Soc Hematol Educ Program,2016,2016(1):24-32.
［12］ MENG FJ,MENG FM,WU HX,et al. miR-564 inhibited metastasis and proliferation of prostate cancer by targeting MLLT3［J］. European Review for Medical and Pharmacological Sciences,2017,21(21)：4828-4834.
［13］ FLEISCHMANN KK,PAGEL P,SCHMID I,et al. RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes［J］. Mol Cancer,2014,13:27.
［14］ HYRENIUS-WITTSTEN A,PILHEDEN M,STURESSON H,et al. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia［J］. Nat Commun,2018,9(1):1770.
［15］ LIU Q,CHEN L,ATKINSON JM,et al. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model［J］. Cell Death Dis,2016,7(9):e2361.
［16］ CHEN X,CLARK J,WUNDERLICH M,et al. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine［J］. Autophagy,2017,13(5):955-966.
［17］ JOH T,HOSOKAWA Y,SUZUKI R,et al. Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7,Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dcl3 cells［J］. Oncogene,1999,18(4):1125-1130.
［18］ KAWAGOE H,KAWAGOE R,SANO K. Targeted down-regulation of MLL-AF9 with antisense oligodeoxyribonucleotide reduces the expression of the HOXA7 and -A10 genes and induces apoptosis in a human leukemia cell line,THP-1［J］. Leukemia,2001,15(11):1743-1749.
［19］ ISSHIKI Y,IWAMA A.Emerging role of noncanonical polycomb repressive complexes in normal and malignant hematopoiesis［J］. Exp Hematol,2018,68:10-14.
［20］ SCHWARTZ YB,PIRROTTA V.A new world of polycombs:unexpected partnerships and emerging functions［J］. Nat Rev Genet,2013,14(12):853-864.
［21］ UI A,NAGAURA Y,YASUI A.Transcriptional elongation factor ENL phosphorylated by ATM recruits polycomb and switches off transcription for DSB repair［J］. Mol Cell,2015,58(3):468-482.
［22］ OKADA Y,FENG Q,LIN Y,et al. hDOT1L links histone methylation to leukemogenesis［J］. Cell,2005,121(2):167-178.
［23］ FAROOQ Z,BANDAY S,PANDITA TK,et al.The many faces of histone H3K79 methylation［J］. Mutat Res Rev Mutat Res,2016,768:46-52.
［24］ KUNTIMADDI A,ACHILLE NJ,THORPE J,et al.Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential［J］. Cell Rep,2015,11(5):808-820.
［25］ SKUCHA A,EBNER J,SCHMOLLERL J,et al. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity［J］. Nat Commun,2018,9(1):1983.
［26］ YOKOYAMA A,LIN M,NARESH A,et al.A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription［J］. Cancer Cell,2010,17(2):198-212.
［27］ MALIK B,HEMENWAY CS.CBX8,a component of the Polycomb PRC1 complex,modulates DOT1L-mediated gene expression through AF9/MLLT3［J］. FEBS Lett,2013,587(18):3038-3044.
［28］ LOKKEN AA,ACHILLE NJ,CHANG MJ,et al. Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4［J］. Leuk Res,2014,38(11):1309-1315.
［29］ NASSA G,SALVATI A,TARALLO R,et al. Inhibition of histone methyltransferase DOT1L silences ERalpha gene and blocks proliferation of antiestrogen-resistant breast cancer cells［J］. Sci Adv,2019,5(2):v5590.
［30］ BASAVAPATHRUNI A,OLHAVA EJ,DAIGLE SR,et al.Nonclinical pharmacokinetics and metabolism of EPZ-5676,a novel DOT1L histone methyltransferase inhibitor［J］. Biopharm Drug Dispos,2014,35(4):237-252.
［31］ PARAMESWARAN S,VIZEACOUMAR FS,KALYANASUNDARA
M BK,et al. Molecular characterizationof an MLL1 fusion and its role in chromosomal instability［J］. Mol Oncol,2019,13(2):422-440.
［32］ DU L,GRIGSBY SM,YAO A,et al.Peptidomimetics for targeting protein-protein interactions between DOT1L and MLL oncofusion proteins AF9 and ENL［J］. ACS Med Chem Lett,2018,9(9):895-900.
［33］ BENNETT CA,WINTERS AC,BARRETTO NN,et al.Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents［J］. Leuk Res,2009,33(7):937-947.
［34］ PARK SM,CHO H,THORNTON AM,et al.IKZF2 drives leukemia stem cell self-renewal and inhibits myeloid differentiation［J］. Cell Stem Cell,2019,24(1):153-165.